Teva Women’s Health, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved the emergency contraceptive Plan B One-Step ® (levonorgestrel) tablet 1.5 mg for over-the-counter sale to all consumers in the United States. This landmark decision represents the continuation of improving access to emergency contraception to all who need it, when they need it. Plan B One-Step ® is the first one pill emergency contraceptive that will be available in store aisles with no age or point-of-sale restrictions, and will not require consumers to show identification in order to purchase it.
“Bringing Plan B One-Step ® out from behind the pharmacy counter helps women tremendously by removing one of the biggest barriers to access and timely use of emergency contraception, which is critically important. Plan B One-Step ® allows women to get what they need with one dose, without waiting 12 hours to take a second pill to complete the regimen,” said Jill DeSimone, Senior Vice President & General Manager, Teva Global Women's Health. “We are committed to ensuring Plan B One-Step ® is available to women who need it as it transitions into the aisle. As such, the price of Plan B One-Step ® to wholesale and retail outlets will remain unchanged. Plan B One-Step ® will also continue to be sold to hospitals and health clinics at a subsidized price for women who may not otherwise be able to afford it.”
“At Teva we are committed to ensuring information, educational tools and healthcare professional support are made available to all those who need it, right at the time that they need it,” continued DeSimone. “These offerings make us a true partner for women as they manage their health through their reproductive years.”